Announcing the receipt of CLIA Waiver for DPP HIV-Syphilis. Contact your local Chembio Representative for more information
![CLIA Waved Badge](https://chembio.com/wp-content/uploads/2023/03/clia-waived-badge-UPDATED.webp)
![Bio Synex Logo](https://chembio.com/wp-content/uploads/2023/04/Biosynex-Newsroom-1920x1080-1-600x403.png)
Biosynex Completes Acquisition of Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG,…
![](https://chembio.com/wp-content/uploads/2022/11/CLIA-submission-2-600x403.jpg)
Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System
MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on…
![Treponema Pallidum Spyrochete](https://chembio.com/wp-content/uploads/2022/11/chembio-post-bg-600x403.jpg)
Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay
HAUPPAUGE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused…
About Us
We enable longer and healthier living through detection and monitoring of infectious diseases at the point of care.
Our mission is to be a leader in the development, manufacturing and commercialization of diagnostic solutions. We are dedicated to delivering exceptional point-of-care products that are easy to use, fast and accurate.